Sign inJoin waitlistJoin the waitlist

Brandi Reeves

Lead Our MPN Program

Credentials: · · ·

History

Present

Research

Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial
Blood · 2020 · 617 citations
Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial
The Lancet Oncology · 2018 · 223 citations
Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1
Journal of Clinical Oncology · 2011 · 216 citations

Paul Richardson
16 papers
Peter Voorhees
16 papers
Cesar Valdes
12 papers
Larry Anderson
12 papers
TL
Thomas Lin
12 papers
Jonathan Kaufman
11 papers
Sarah Holstein
11 papers
Ajai Chari
10 papers
AJ
Andrzej Jakubowiak
10 papers
Luciano Costa
9 papers
Tanya Wildes
9 papers
Douglas Sborov
8 papers

Grants

Hypoxia-Inducible Factors and Neutrophil Heterogeneity in Myeloproliferative Neoplasm-Associated Venous Thrombosis
National Heart, Lung, and Blood Institute · K08
Contact PI · $564.8K · Univ of North Carolina Chapel Hill
2023–2028

Clinical trials

Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma
Principal investigator · Terminated · Phase 1
UNC Lineberger Comprehensive Cancer Center
2008–2015